GlassScriptPhysician profile
Matthew Paoli
NPI 1144589235
$1,151.54
in general payments reported to CMS, 2019-2025
25 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.80 · 2023: $16.60 · 2024: $549 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.36 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $172.20 | 2024-2025 | |
| Exact Sciences Corporation | $98.55 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $95.20 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $89.50 | 2023-2025 | |
| Lilly USA, LLC | $78.46 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $76.35 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bausch Health US, LLC | $37.61 | 2024-2025 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.95 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.77 | 2024-2025 | Jardiance, Synjardy |
| Amgen INC. | $29.58 | 2025 | Repatha, Otezla |
| Insightec,INC | $24.75 | 2025 | Exablate |
| Novartis Pharmaceuticals Corporation | $21.72 | 2024 | |
| Corcept Therapeutics | $21.56 | 2024 | Korlym |
| Philips North America LLC | $17.51 | 2024 | (5050) Extended Holter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.00 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $16.72 | 2025 | Contrave |
| Axsome Therapeutics, INC. | $16.48 | 2025 | Sunosi |
| Hologic Sales and Service, LLC | $16.44 | 2025 | Aptima |
| Watermark Medical, INC. | $15.02 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.98 | 2025 | Voquezna |
| Lundbeck LLC | $14.78 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $13.64 | 2025 | Qelbree |
| Xeris Pharmaceuticals, INC. | $13.61 | 2025 | Keveyis |
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Paoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.